- Apply to an adult with unstable angina or non-ST-elevation myocardial infarction after an initial 12-lead EKG and cardiac biomarker (troponin or CK-MB) have been obtained.
- Check each of the seven items that is present (worth 1 point each). Leave unchecked boxes as absent (0 points).
- The total TIMI Risk Score is 0–7. The 14-day composite risk (all-cause mortality, new or recurrent myocardial infarction, or severe recurrent ischemia prompting urgent revascularization) updates automatically.
- Higher scores identify patients who derive greater benefit from low-molecular-weight heparin (TIMI 11B / ESSENCE) and from an early invasive strategy (TACTICS-TIMI 18).
All computation runs in your browser; no values are stored or transmitted.
When to Use
Use the TIMI Risk Score in adults with confirmed or strongly suspected unstable angina or NSTEMI to quantify short-term (14-day) risk of death, new or recurrent myocardial infarction, or severe recurrent ischemia requiring urgent revascularization. It was derived in the TIMI 11B and ESSENCE trials and is most helpful when deciding between an early invasive and a more conservative management strategy.
Appropriate population
Adults with unstable angina or NSTEMI who have undergone an initial EKG and cardiac biomarker assay. The score has been validated across multiple acute coronary syndrome cohorts and remains a standard risk-stratification tool in combination with current guideline-directed care.
When NOT to rely on it
Do not apply to patients with ST-elevation myocardial infarction (STEMI) — use the TIMI STEMI score instead. For undifferentiated chest pain in the emergency department (acute coronary syndrome not yet established), the HEART Score was derived for that specific setting and performs better. For in-hospital or 6-month mortality in confirmed acute coronary syndrome, the GRACE score has broader calibration. TIMI does not substitute for current serial troponin trajectories or hemodynamic and electrical risk assessment.
Pearls & Pitfalls
Treatment benefit tracks the score
In TIMI 11B and ESSENCE, enoxaparin outperformed unfractionated heparin most clearly as the TIMI Risk Score rose above 2. In TACTICS-TIMI 18, the early invasive strategy produced the greatest absolute benefit in moderate-to-high-risk patients (scores ≥ 3). The score is not just prognostic — it identifies the group most likely to be helped by escalation.
Count risk factors carefully
The "≥ 3 CAD risk factors" item counts hypertension, hypercholesterolemia, diabetes mellitus, current cigarette smoking, and family history of premature coronary artery disease. A documented personal history of coronary disease is a separate item ("Known CAD: prior coronary stenosis ≥ 50%"). Do not double-count.
Pitfalls
(1) The score is dichotomous — a single ST-segment deviation of 0.5 mm counts the same as marked ST depression. Always interpret with the EKG itself. (2) "Severe angina" means at least two anginal episodes in the preceding 24 hours; one episode does not count. (3) The score does not adjust for renal function, heart failure, or hemodynamic instability — these are powerful modifiers that the GRACE score captures better. (4) The 14-day event rates below are from the TIMI 11B derivation cohort and should be interpreted alongside contemporary care (dual antiplatelet therapy, high-intensity statin, early invasive strategy as indicated), which lowers absolute event rates.
Why Use It
The TIMI Risk Score for unstable angina/NSTEMI, derived by Antman and colleagues in the TIMI 11B and ESSENCE enoxaparin trials, is one of the oldest and best-studied acute coronary syndrome risk scores. Its strengths are its simplicity (seven dichotomous items, computable at the bedside in seconds) and its decision utility: the score has been shown in randomized data to identify the patients who benefit most from low-molecular-weight heparin over unfractionated heparin and from an early invasive strategy over conservative management. It remains a common risk-stratification tool in acute coronary syndrome guidelines and in internal medicine training, though it is now typically used alongside, rather than instead of, the GRACE score and current serial troponin strategies.
TIMI Risk Score — Unstable Angina / NSTEMI
Check each item that is present. The total TIMI Risk Score (0–7), the 14-day composite event rate, and treatment-benefit guidance update automatically.
⚕ Antman EM, Cohen M, Bernink PJLM, et al. JAMA. 2000;284(7):835–842. The 14-day composite endpoint is all-cause mortality, new or recurrent myocardial infarction, and severe recurrent ischemia prompting urgent revascularization, from the TIMI 11B derivation cohort. For licensed clinicians; not a substitute for individualized assessment.
Next Steps
Use the TIMI Risk Score to classify short-term risk, choose antithrombotic therapy, and time coronary angiography.
- Low score (0 – 2): 14-day composite 4.7% (score 0–1) to 8.3% (score 2). A conservative, ischemia-guided strategy is reasonable in most of these patients; continue dual antiplatelet therapy and anticoagulation and reassess with serial troponins.
- Moderate score (3 – 4): 14-day composite 13.2% to 19.9%. Both TIMI 11B/ESSENCE (low-molecular-weight heparin over unfractionated heparin) and TACTICS-TIMI 18 (early invasive strategy) showed substantial benefit at this risk level.
- High score (5 – 7): 14-day composite 26.2% to 40.9%. Early invasive strategy (angiography within 24 – 48 hours) is strongly favored; prioritize guideline-directed acute coronary syndrome therapy and cardiology consultation.
- Pair this with the GRACE ACS score for in-hospital and 6-month mortality, and the HEART Score for undifferentiated emergency-department chest pain.
Evidence & References
Seven-Item TIMI Risk Score
| Item (1 point each if present) |
|---|
| Age ≥ 65 years |
| ≥ 3 coronary artery disease risk factors (hypertension, hypercholesterolemia, diabetes, current smoking, family history of premature coronary artery disease) |
| Known coronary artery disease (prior stenosis ≥ 50%) |
| Aspirin use in the prior 7 days |
| Severe angina (≥ 2 episodes in the preceding 24 hours) |
| ST deviation ≥ 0.5 mm on the presenting EKG |
| Positive cardiac biomarkers (troponin or CK-MB) |
14-day Composite Event Rate by Score (TIMI 11B)
| Score | Mortality, new/recurrent MI, or severe recurrent ischemia with urgent revascularization |
|---|---|
| 0 – 1 | 4.7% |
| 2 | 8.3% |
| 3 | 13.2% |
| 4 | 19.9% |
| 5 | 26.2% |
| 6 – 7 | 40.9% |
The composite endpoint was defined in the TIMI 11B trial as all-cause mortality, new or recurrent myocardial infarction, or severe recurrent ischemia prompting urgent revascularization within 14 days. Higher scores predicted greater absolute benefit from enoxaparin over unfractionated heparin in TIMI 11B and ESSENCE, and from an early invasive strategy in TACTICS-TIMI 18.
References
- Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–842. doi:10.1001/jama.284.7.835.
